ES2129442T3 - Sintesis de mezclas de oligomeros multiples equimolares, especialmente de mezclas oligopeptidicas. - Google Patents

Sintesis de mezclas de oligomeros multiples equimolares, especialmente de mezclas oligopeptidicas.

Info

Publication number
ES2129442T3
ES2129442T3 ES92902209T ES92902209T ES2129442T3 ES 2129442 T3 ES2129442 T3 ES 2129442T3 ES 92902209 T ES92902209 T ES 92902209T ES 92902209 T ES92902209 T ES 92902209T ES 2129442 T3 ES2129442 T3 ES 2129442T3
Authority
ES
Spain
Prior art keywords
mixtures
synthesis
amino acid
disclosed
coupled
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92902209T
Other languages
English (en)
Inventor
Richard A Houghten
Julio Hernan Cuervo
Clemencia Pinilla
Jon R Appel Jr
Silvie Blondelle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ITEREX PHARMA LP
Original Assignee
ITEREX PHARMA LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ITEREX PHARMA LP filed Critical ITEREX PHARMA LP
Application granted granted Critical
Publication of ES2129442T3 publication Critical patent/ES2129442T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J19/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J19/0046—Sequential or parallel reactions, e.g. for the synthesis of polypeptides or polynucleotides; Apparatus and devices for combinatorial chemistry or for making molecular arrays
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00277—Apparatus
    • B01J2219/00279—Features relating to reactor vessels
    • B01J2219/00281—Individual reactor vessels
    • B01J2219/00295—Individual reactor vessels the reactor vessels having pervious side walls
    • B01J2219/00297—"Tea bags"
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00277—Apparatus
    • B01J2219/00457—Dispensing or evacuation of the solid phase support
    • B01J2219/00459—Beads
    • B01J2219/00461—Beads and reaction vessel together
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00277—Apparatus
    • B01J2219/00497—Features relating to the solid phase supports
    • B01J2219/005—Beads
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583—Features relative to the processes being carried out
    • B01J2219/00585—Parallel processes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583—Features relative to the processes being carried out
    • B01J2219/0059—Sequential processes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583—Features relative to the processes being carried out
    • B01J2219/00592—Split-and-pool, mix-and-divide processes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583—Features relative to the processes being carried out
    • B01J2219/00596—Solid-phase processes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00718—Type of compounds synthesised
    • B01J2219/0072—Organic compounds
    • B01J2219/00725—Peptides
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B60/00—Apparatus specially adapted for use in combinatorial chemistry or with libraries
    • C40B60/14—Apparatus specially adapted for use in combinatorial chemistry or with libraries for creating libraries

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polyamides (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)

Abstract

SE MUESTRA UN PROCESO PARA LA SINTESIS DE UNA AGRUPACION DE MEZCLA COMPLEJA DE COMPUESTOS DE UNIDAD REPETIDORA MONOMERICA ACOPLADA A SOPORTE SOLIDO COMO DERIVADOS DE AMINOACIDO EN EL CUAL LA AGRUPACION DE MEZCLA CONTIENE UNA REPRESENTACION EQUIMOLAR DE COMPUESTOS DE UNIDAD REPETIDORA MONOMERICA REACCIONADOS ACOPLADOS. TAMBIEN SE MUESTRA UN PROCESO PARA LA SINTESIS PROGRESIVA DE UNA MEZCLA COMPLEJA DE OLIGOMEROS NO SOPORTADOS LIBRES O ACOPLADOS, POR EJEMPLO OLIGOPEPTIDOS. TAMBIEN SE MUESTRA UN GRUPO DE OLIGOPEPTIDOS MEZCLADOS NO SOPORTADOS AUTOSOLUBILIZANTES CON UNO O MAS RESIDUOS DE AMINOACIDOS PREDETERMINADOS EN UNO O MAS DE LAS MISMAS POSICIONES PREDETERMINADAS EN LA CADENA DE OLIGOPEPTIDOS EN DONDE EL GRUPO CONTIENE CANTIDADES EQUIMOLARES DE UNA SERIE DE RESIDUOS DE AMINOACIDOS DIFERENTES, PREFERENTEMENTE AL MENOS SEIS RESIDUOS DIFERENTES, EN UNA O MAS POSICIONES PREDETERMINADAS DE LA CADENA DE OLIGOPEPTIDOS, ASI COMO METODOS PARA PRODUCIR Y UTILIZAR LOS MISMOS.
ES92902209T 1990-11-21 1991-11-20 Sintesis de mezclas de oligomeros multiples equimolares, especialmente de mezclas oligopeptidicas. Expired - Lifetime ES2129442T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61702390A 1990-11-21 1990-11-21
US70165891A 1991-05-16 1991-05-16
US79755191A 1991-11-19 1991-11-19

Publications (1)

Publication Number Publication Date
ES2129442T3 true ES2129442T3 (es) 1999-06-16

Family

ID=27417190

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92902209T Expired - Lifetime ES2129442T3 (es) 1990-11-21 1991-11-20 Sintesis de mezclas de oligomeros multiples equimolares, especialmente de mezclas oligopeptidicas.

Country Status (11)

Country Link
US (2) US5556762A (es)
EP (1) EP0558671B1 (es)
JP (1) JP3523252B2 (es)
AT (1) ATE176239T1 (es)
AU (1) AU668347B2 (es)
CA (1) CA2090860C (es)
DE (1) DE69130831T2 (es)
DK (1) DK0558671T3 (es)
ES (1) ES2129442T3 (es)
GR (1) GR3030061T3 (es)
WO (1) WO1992009300A1 (es)

Families Citing this family (268)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197529B1 (en) 1990-11-21 2001-03-06 Torrey Pines Institute For Molecular Studies Linear substituted oligoalkyleneimine libraries
AU668347B2 (en) * 1990-11-21 1996-05-02 Torrey Pines Institute For Molecular Studies Synthesis of equimolar multiple oligomer mixtures, especially of oligopeptide mixtures
NZ243090A (en) * 1991-06-18 1993-11-25 Lilly Co Eli Method of identifying active peptides and synthesis of peptide mixtures with a known amino acid in the last coupled position
WO1993004204A1 (en) * 1991-08-23 1993-03-04 Isis Pharmaceuticals, Inc. Synthetic unrandomization of oligomer fragments
US5747253A (en) * 1991-08-23 1998-05-05 Isis Pharmaceuticals, Inc. Combinatorial oligomer immunoabsorbant screening assay for transcription factors and other biomolecule binding
EP0604552B1 (en) * 1991-09-18 1997-02-12 Affymax Technologies N.V. Method of synthesizing diverse collections of oligomers
US5646119A (en) * 1991-11-01 1997-07-08 Periodontix, Inc. D-amino acid histatin-based peptides as anti-fungal and anti-bacterial agents
US5885965A (en) * 1991-11-01 1999-03-23 Periodontix, Inc. Anti-fungal D-amino acid histatin-based peptides
US5573905A (en) * 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5541061A (en) * 1992-04-29 1996-07-30 Affymax Technologies N.V. Methods for screening factorial chemical libraries
CA2137378C (en) * 1992-06-05 2008-08-05 Stephen Brian Henry Kent D-enzyme compositions and methods of their use
US5721099A (en) * 1992-10-01 1998-02-24 Trustees Of Columbia University In The City Of New York Complex combinatorial chemical libraries encoded with tags
US6503759B1 (en) 1992-10-01 2003-01-07 The Trustees Of Columbia University In The City Of New York Complex combinatorial chemical libraries encoded with tags
US5565324A (en) * 1992-10-01 1996-10-15 The Trustees Of Columbia University In The City Of New York Complex combinatorial chemical libraries encoded with tags
US5807683A (en) * 1992-11-19 1998-09-15 Combichem, Inc. Combinatorial libraries and methods for their use
WO1994020521A1 (de) * 1993-03-12 1994-09-15 Jerini Bio Chemicals Gmbh Verfahren zur synthese und selektionierung von sequenzen aus kovalent verbundenen bausteinen
US5786327A (en) 1993-03-12 1998-07-28 Gensci Regeneration Sciences Inc. Bone stimulating factor, methods of isolating same, and methods of increasing bone growth comprising administering same
US6864048B2 (en) * 1993-04-28 2005-03-08 Affymetrix, Inc. Factorial chemical libraries
US5480971A (en) * 1993-06-17 1996-01-02 Houghten Pharmaceuticals, Inc. Peralkylated oligopeptide mixtures
US5846731A (en) * 1993-06-17 1998-12-08 Torry Pines Institute For Molecular Studies Peralkylated oligopeptide mixtures
EP0788370A4 (en) 1993-07-09 1998-07-08 Smithkline Beecham Corp CYCLIC, PARTIAL RANDOM PEPTIDE LIBRARIES
WO1995003315A2 (en) * 1993-07-21 1995-02-02 Oxford Glycosystems Ltd Saccharides, their synthesis and use
CN1525171A (zh) * 1993-10-01 2004-09-01 ŦԼ�и��ױ��Ǵ�ѧ���� 用标示物编码的多元组合化学库
EP0725838A4 (en) * 1993-10-26 1997-02-26 United Biomedical Inc STRUCTURED SYNTHETIC ANTIGAN BANKS AS DIAGNOSTICS, VACCINE AND THERAPEUTIC AGENTS
US5503805A (en) * 1993-11-02 1996-04-02 Affymax Technologies N.V. Apparatus and method for parallel coupling reactions
US6287787B1 (en) 1993-11-24 2001-09-11 Torrey Pines Institute For Molecular Studies Dimeric oligopeptide mixture sets
US5965536A (en) * 1993-12-15 1999-10-12 Board Of Regents, The University Of Texas System Methods of inhibiting CXC intercrine molecules
ATE160223T1 (de) * 1993-12-15 1997-11-15 Combichem Inc Kombinatorische bibliotheken und verfahren zu ihrer verwendung
FI962413L (fi) * 1993-12-15 1996-07-24 Univ Texas CXC-interkriinimolekyylien peptidi-inhibiittoreita
US5587471A (en) * 1994-01-11 1996-12-24 Isis Pharmaceuticals, Inc. Method of making oligonucleotide libraries
JPH09511486A (ja) * 1994-01-13 1997-11-18 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク 合成レセプター、ライブラリー及びこれらの使用
US6936477B2 (en) 1994-04-13 2005-08-30 The Trustees Of Columbia University In The City Of New York Complex combinatorial chemical libraries encoded with tags
US5824483A (en) * 1994-05-18 1998-10-20 Pence Inc. Conformationally-restricted combinatiorial library composition and method
US5738996A (en) * 1994-06-15 1998-04-14 Pence, Inc. Combinational library composition and method
US5939268A (en) * 1994-07-26 1999-08-17 The Scripps Research Institute Combinatorial libraries of molecules and methods for producing same
US5645996A (en) * 1994-08-24 1997-07-08 Torrey Pines Institute For Molecular Studies Melittin-related polypeptides, mixture sets and libraries thereof
US5582997A (en) * 1994-08-24 1996-12-10 Torrey Pines Institute For Molecular Studies Lysine/leucine polypeptides, mixture sets and libraries thereof
US5885782A (en) * 1994-09-13 1999-03-23 Nce Pharmaceuticals, Inc. Synthetic antibiotics
US5602097A (en) * 1994-09-13 1997-02-11 Ceres Technologies, Inc. Synthetic antibiotics
US6020312A (en) * 1994-09-13 2000-02-01 Nce Pharmaceuticals, Inc. Synthetic antibiotics
US20020169104A1 (en) * 1997-05-01 2002-11-14 Glenn Frank Novel ectoparasite saliva proteins and apparatus to collect such proteins
US6025129A (en) * 1995-04-25 2000-02-15 Irori Remotely programmable matrices with memories and uses thereof
US6331273B1 (en) 1995-04-25 2001-12-18 Discovery Partners International Remotely programmable matrices with memories
US6017496A (en) 1995-06-07 2000-01-25 Irori Matrices with memories and uses thereof
US5925562A (en) * 1995-04-25 1999-07-20 Irori Remotely programmable matrices with memories
US5751629A (en) 1995-04-25 1998-05-12 Irori Remotely programmable matrices with memories
US6329139B1 (en) 1995-04-25 2001-12-11 Discovery Partners International Automated sorting system for matrices with memory
US5874214A (en) 1995-04-25 1999-02-23 Irori Remotely programmable matrices with memories
US5741462A (en) 1995-04-25 1998-04-21 Irori Remotely programmable matrices with memories
US6416714B1 (en) 1995-04-25 2002-07-09 Discovery Partners International, Inc. Remotely programmable matrices with memories
US6352973B1 (en) * 1995-06-07 2002-03-05 Osteopharm Inc. Bone stimulating factor
US6693081B2 (en) * 1995-09-26 2004-02-17 Osteopharm Inc. Bone stimulating factor
US5763263A (en) * 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
US6277583B1 (en) 1996-02-07 2001-08-21 Conjuchem, Inc. Affinity labeling libraries and applications thereof
US6121489A (en) * 1996-03-05 2000-09-19 Trega Biosciences, Inc. Selectively N-alkylated peptidomimetic combinatorial libraries and compounds therein
WO1998013377A1 (en) * 1996-03-06 1998-04-02 Biomolecular Research Institute Ltd. Cytotoxic peptides
US20020142352A1 (en) * 1999-03-04 2002-10-03 Heska Corporation Novel ectoparasite salvia proteins and apparatus to collect such proteins
US6110889A (en) * 1996-06-14 2000-08-29 Board Of Regents, The University Of Texas System Peptide tumor cell growth inhibitors
US5804436A (en) * 1996-08-02 1998-09-08 Axiom Biotechnologies, Inc. Apparatus and method for real-time measurement of cellular response
US6558916B2 (en) 1996-08-02 2003-05-06 Axiom Biotechnologies, Inc. Cell flow apparatus and method for real-time measurements of patient cellular responses
US6280967B1 (en) 1996-08-02 2001-08-28 Axiom Biotechnologies, Inc. Cell flow apparatus and method for real-time of cellular responses
AUPO161196A0 (en) * 1996-08-13 1996-09-05 Commonwealth Scientific And Industrial Research Organisation Novel compounds
WO1998015825A2 (en) * 1996-10-07 1998-04-16 Irori Matrices with memories in automated drug discovery and units therefor
DE19643314A1 (de) * 1996-10-21 1998-04-23 Boehringer Mannheim Gmbh Monoklonale Antikörper gegen das Epitop YPYDVPDYA, Verfahren zu deren Herstellung und Verwendung
US6617114B1 (en) 1996-10-31 2003-09-09 Karo Bio Ab Identification of drug complementary combinatorial libraries
US6441172B1 (en) 1996-11-07 2002-08-27 Torrey Pines Institute For Molecular Studies Diketodiazacyclic compounds, diazacyclic compounds and combinatorial libraries thereof
US5859191A (en) * 1996-12-05 1999-01-12 The Regents Of The University Of California Method for the site-specific modification of peptide alpha amines
WO1998029736A1 (en) 1996-12-31 1998-07-09 Genometrix Incorporated Multiplexed molecular analysis apparatus and method
US6262269B1 (en) 1997-02-04 2001-07-17 Trega Biosciences, Inc. 4-Substituted-quinoline derivatives and 4-substituted-quinoline combinatorial libraries
US6004823A (en) * 1997-05-07 1999-12-21 Smithkline Beecham Corporation Compounds
US5908960A (en) * 1997-05-07 1999-06-01 Smithkline Beecham Corporation Compounds
CA2289719A1 (en) * 1997-05-08 1998-11-12 Ravi S. Garigipati Chloride linker for solid phase organic synthesis
ATE406577T1 (de) 1997-11-07 2008-09-15 Conjuchem Biotechnologies Inc Methoden zum screening von affinitätsmarker- bibliotheken
US6190920B1 (en) 1997-11-12 2001-02-20 The Regents Of The University Of California Method for detecting enzyme catalyzed cyclization
US20100105572A1 (en) * 1997-12-19 2010-04-29 Kris Richard M High throughput assay system
US20030096232A1 (en) * 1997-12-19 2003-05-22 Kris Richard M. High throughput assay system
US20030039967A1 (en) * 1997-12-19 2003-02-27 Kris Richard M. High throughput assay system using mass spectrometry
GB9808783D0 (en) * 1998-04-25 1998-06-24 Central Research Lab Ltd Labelling of small articles
US6541211B1 (en) * 1998-05-20 2003-04-01 Selectide Corporation Apparatus and method for synthesizing combinational libraries
US6872535B2 (en) * 1998-05-20 2005-03-29 Aventis Pharmaceuticals Inc. Three-dimensional array of supports for solid-phase parallel synthesis and method of use
US7060431B2 (en) 1998-06-24 2006-06-13 Illumina, Inc. Method of making and decoding of array sensors with microspheres
DK1129354T3 (da) * 1998-11-13 2008-11-10 Pepscan Systems Bv Fremgangsmåde til bestemmelse af en mimotopsekvens
US6846460B1 (en) 1999-01-29 2005-01-25 Illumina, Inc. Apparatus and method for separation of liquid phases of different density and for fluorous phase organic syntheses
EP1147229A2 (en) 1999-02-02 2001-10-24 Bernhard O. Palsson Methods for identifying drug targets based on genomic sequence data
US6500609B1 (en) 1999-02-11 2002-12-31 Scynexis Chemistry & Automation, Inc. Method and apparatus for synthesizing characterizing and assaying combinatorial libraries
US6362342B1 (en) 1999-06-29 2002-03-26 Lion Bioscience Ag Triazole compounds and methods of making same
US6524863B1 (en) 1999-08-04 2003-02-25 Scynexis Chemistry & Automation, Inc. High throughput HPLC method for determining Log P values
US6413431B1 (en) 1999-08-10 2002-07-02 Scynexis Chemistry & Automation, Inc. HPLC method for purifying organic compounds
ATE542916T1 (de) 1999-08-18 2012-02-15 Illumina Inc Methoden zur erzeugung von oligonukleotidlösungen
EP1212128A1 (en) 1999-08-27 2002-06-12 Scynexis Chemistry and Automation, Inc. Sample preparation for high throughput purification
US6432409B1 (en) * 1999-09-14 2002-08-13 Antigen Express, Inc. Hybrid peptides modulate the immune response
US9289487B2 (en) * 1999-09-14 2016-03-22 Antigen Express, Inc. II-key/antigenic epitope hybrid peptide vaccines
US20030235594A1 (en) * 1999-09-14 2003-12-25 Antigen Express, Inc. Ii-Key/antigenic epitope hybrid peptide vaccines
US6545032B1 (en) 1999-09-17 2003-04-08 Torrey Pines Institute For Molecular Studies Synthesis of [3,5,7]-H-imidazo[1,5-a] imidazol-2(3H)-one compounds
US6632616B2 (en) * 2000-03-16 2003-10-14 Duke University Compounds that selectively bind to expanded polyglutamine repeat domains and methods of use thereof
IL153359A0 (en) * 2000-06-16 2003-07-06 Hercules Inc Peptides, compositions and methods for the treatment of burkholderia cepacia
PL363153A1 (en) * 2000-06-16 2004-11-15 Hercules Incorporated Chemically-modified antimicrobial peptides, compositions and methods of production and use
AU2001270098A1 (en) * 2000-06-22 2002-01-02 San Diego State University Foundation Recombination modulators and methods for their production and use
US6759510B1 (en) * 2000-06-30 2004-07-06 Becton, Dickinson And Company Peptides for use in culture media
JP5305553B2 (ja) 2000-10-12 2013-10-02 ユニバーシティー オブ ロチェスター 癌細胞の増殖を阻害する組成物
US20040229382A1 (en) * 2000-10-23 2004-11-18 Ronald Breaker Characterized arrangements of mixtures (CAM) using polymers
DE10059890A1 (de) * 2000-12-01 2002-06-20 Hte Ag Verfahren zur Herstellung einer Vielzahl von Bausteinen einer Materialbibliothek
AUPR279101A0 (en) * 2001-01-30 2001-02-22 Cytopia Pty Ltd Protein kinase signalling
US7127379B2 (en) * 2001-01-31 2006-10-24 The Regents Of The University Of California Method for the evolutionary design of biochemical reaction networks
EP1381860A4 (en) * 2001-03-01 2008-10-15 Univ California MODELS AND METHOD FOR DETERMINING SYSTEMIC PROPERTIES OF REGULATED RESPONSE NETWORKS
US7265208B2 (en) 2001-05-01 2007-09-04 The Regents Of The University Of California Fusion molecules and treatment of IgE-mediated allergic diseases
JP4538192B2 (ja) 2001-05-01 2010-09-08 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア 免疫疾患を治療するための融合分子及び方法
US7138506B2 (en) 2001-05-09 2006-11-21 Genetic Id, Na, Inc. Universal microarray system
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
JP4342934B2 (ja) 2001-06-11 2009-10-14 キセノポート インコーポレーティッド Ｐｅｐｔ−２輸送体を介した薬剤の投与
EP1409549A4 (en) 2001-06-20 2007-10-24 Genentech Inc COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMORS
US7803915B2 (en) 2001-06-20 2010-09-28 Genentech, Inc. Antibody compositions for the diagnosis and treatment of tumor
JP4351043B2 (ja) 2001-07-09 2009-10-28 エラン ファーマシューティカルズ，インコーポレイテッド アミロイド毒性の阻害方法
CN1213062C (zh) * 2001-07-13 2005-08-03 一泰医药研究（深圳）有限公司 序列号13的生物活性肽
NZ573739A (en) 2001-09-18 2010-07-30 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor, particularly colorectal tumor - TAT201
US20030228319A1 (en) 2002-04-16 2003-12-11 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7751981B2 (en) 2001-10-26 2010-07-06 The Regents Of The University Of California Articles of manufacture and methods for modeling Saccharomyces cerevisiae metabolism
WO2003045974A2 (en) * 2001-11-21 2003-06-05 The Burnham Institute Methods and compositions for derepression of iap-inhibited caspase
US20050119176A1 (en) * 2001-11-21 2005-06-02 The Burnham Institute Methods and compositions for derepression of IAP-inhibited caspase
US20060258581A1 (en) * 2001-11-21 2006-11-16 Reed John C Methods and composition for derepressions of IAP-inhibited caspase
EP1575571A4 (en) 2002-01-02 2008-06-25 Genentech Inc COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF A TUMOR
EP1572168B1 (en) 2002-02-06 2010-05-26 Vicor Technologies, Inc. Anti-infarction molecules
US6861523B2 (en) 2002-02-08 2005-03-01 Torrey Pines Institute For Molecular Studies 1,3,5- trisubstituted-1,3,5-triazine-2,4,6-trione compounds and libraries
US20030224363A1 (en) * 2002-03-19 2003-12-04 Park Sung M. Compositions and methods for modeling bacillus subtilis metabolism
JP2005521929A (ja) 2002-03-29 2005-07-21 ジェノマティカ・インコーポレイテッド ヒト代謝モデルおよび方法
US8949032B2 (en) 2002-03-29 2015-02-03 Genomatica, Inc. Multicellular metabolic models and methods
CA2482995C (en) * 2002-04-22 2013-01-29 Dow Global Technologies Inc. Low-cost production of peptides
EP2305710A3 (en) 2002-06-03 2013-05-29 Genentech, Inc. Synthetic antibody phage libraries
US7856317B2 (en) 2002-06-14 2010-12-21 Genomatica, Inc. Systems and methods for constructing genomic-based phenotypic models
US20050287648A1 (en) 2002-08-05 2005-12-29 University Of Rochester Protein Transducing Domain/Deaminase Chimeric Proteins, Related Compounds, and Uses Thereof
JP2006512901A (ja) * 2002-08-29 2006-04-20 ジェネンテック・インコーポレーテッド Ａｃｈａｅｔｅ−Ｓｃｕｔｅ様−２ポリペプチドとそのコード化核酸並びに腫瘍の診断と治療のための方法
CA2499123A1 (en) 2002-09-17 2004-04-15 Antigen Express, Inc. Ii-key/antigenic epitope hybrid peptide vaccines
US7179645B2 (en) * 2002-09-24 2007-02-20 Antigen Express, Inc. Ii-Key/antigenic epitope hybrid peptide vaccines
JP5064656B2 (ja) 2002-10-15 2012-10-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 実施反応経路を同定するための方法およびシステム
US7869957B2 (en) 2002-10-15 2011-01-11 The Regents Of The University Of California Methods and systems to identify operational reaction pathways
WO2004048529A2 (en) * 2002-11-22 2004-06-10 Incyte Corporation Cell adhesion and extracellular matrix proteins
CA2508765A1 (en) * 2002-12-05 2004-06-17 Osteopharm Inc. Bone growth factor
CA2520789A1 (en) * 2003-03-28 2004-10-14 The Rockefeller University Peptides for reducing symptoms of toxic shock syndrome and septic shock
DK1641822T3 (da) 2003-07-08 2013-07-22 Genentech Inc Heterologe il-17-a/f-polypeptider og terapeutiske anvendelser deraf.
NZ576411A (en) 2003-11-17 2010-04-30 Genentech Inc Compositions and methods for the treatment of tumor of hematopoietic origin
US20050136538A1 (en) * 2003-12-17 2005-06-23 Srikant Pathak Lithographic method for attaching biological cells to a solid substrate using a small molecule linker
WO2005113147A2 (en) 2004-04-08 2005-12-01 Biomatrica, Inc. Integration of sample storage and sample management for life science
US20050261474A1 (en) * 2004-05-20 2005-11-24 Mixture Sciences, Inc. Method of support-based chemical synthesis
EP1600455A1 (en) * 2004-05-28 2005-11-30 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Preparation of solid phase bound peptides or PNAs
US7488804B2 (en) 2005-02-02 2009-02-10 The Regents Of The University Of California Modified fusion molecules for treatment of allergic disease
MX2007010922A (es) 2005-03-10 2007-10-12 Genentech Inc Metodos y composiciones para modular la integridad vascular.
US20070003535A1 (en) 2005-03-17 2007-01-04 Reed John C Methods and compositions for derepression of IAP-inhibited caspase
US8076090B2 (en) 2005-04-05 2011-12-13 Corning Incorporated Label free biosensors and cells
WO2006127020A1 (en) 2005-05-19 2006-11-30 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention FUNCTIONAL EPITOPES OF STREPTOCOCCUS PNEUMONIAE PsaA ANTIGEN AND USES THEREOF
WO2006132788A2 (en) 2005-06-06 2006-12-14 Genentech, Inc. Transgenic models for different genes and their use for gene characterization
EP1995321A2 (en) 2005-08-15 2008-11-26 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
EP2395076A1 (en) 2005-10-14 2011-12-14 MUSC Foundation For Research Development Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy
US8080534B2 (en) 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
US7576037B2 (en) 2005-11-18 2009-08-18 Mei Technologies, Inc. Process and apparatus for combinatorial synthesis
WO2007081608A2 (en) 2005-11-21 2007-07-19 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
JP2009518314A (ja) 2005-12-02 2009-05-07 ジェネンテック・インコーポレーテッド Ｉｌ−２２に結合する抗体およびｉｌ−２２ｒに結合する抗体を含む、サイトカインシグナリングに関連する疾患および障害の処置のための組成物および方法
CA2638821A1 (en) 2006-02-17 2007-10-11 Genentech, Inc. Gene disruptons, compositions and methods relating thereto
CA2647277A1 (en) 2006-04-05 2007-11-08 Genentech, Inc. Method for using boc/cdo to modulate hedgehog signaling
CA2649387A1 (en) 2006-04-19 2008-03-27 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
US20090142259A1 (en) * 2006-05-12 2009-06-04 Genentech, Inc. Compositions and methods for the diagnosis and treatment of bladder and urinary tract tumors
CA2660286A1 (en) 2006-08-09 2008-02-21 Homestead Clinical Corporation Organ-specific proteins and methods of their use
EP2061906B1 (en) 2006-09-12 2011-08-31 Genentech, Inc. Methods and compositions for the diagnosis and treatment of lung cancer using pdgfra, kit or kdr gene as genetic marker
EP2066812A4 (en) 2006-09-21 2010-04-28 Univ Rochester COMPOSITIONS AND METHODS RELATED TO PROTEIN SHIFT THERAPY FOR MYOTONE DYSTROPHY
US7834140B2 (en) * 2006-10-12 2010-11-16 Saint Louis University Polypeptide fragment of constitutive coactivator of PPARgamma
WO2008136852A2 (en) 2006-11-01 2008-11-13 University Of Rochester Methods and compositions related to the structure and function of apobec3g
US9316633B2 (en) 2006-11-16 2016-04-19 The Regents Of The University Of California Methods for identifying inhibitors of solute transporters
JP2010514839A (ja) 2007-01-03 2010-05-06 バーナム インスティテュート フォー メディカル リサーチ クロット結合化合物に関連する方法および組成物
WO2008098182A1 (en) 2007-02-08 2008-08-14 University Of Utah Research Foundation Methods and compositions related to inhibition of viral entry
RU2502806C2 (ru) 2007-02-22 2013-12-27 Дженентек, Инк. Способы выявления воспалительного заболевания кишечника
WO2009012143A2 (en) * 2007-07-13 2009-01-22 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Virus derived antimicrobial peptides
US20090023182A1 (en) * 2007-07-18 2009-01-22 Schilling Christophe H Complementary metabolizing organisms and methods of making same
KR20100059863A (ko) * 2007-09-11 2010-06-04 몬도바이오테크 래보래토리즈 아게 치료제로서의 펩티드 티모신 베타 ４ 단독 또는 세크로핀 ａ와의 배합물의 용도
WO2009033667A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
US20100204131A1 (en) * 2007-09-11 2010-08-12 Dorian Bevec Use of a peptide as a therapeutic agent
EP2205971A4 (en) * 2007-10-04 2011-03-30 Bionomics Ltd ENDOTHEL CELL MARKERS AND USES THEREOF
US20090202475A1 (en) 2007-11-07 2009-08-13 Genentech, Inc. Compositions and methods for treatment of microbial disorders
US20110015239A1 (en) 2007-12-14 2011-01-20 The Regents Of The University Of California Inhibitors of calcium-activated chloride channels
US8301393B2 (en) 2008-02-19 2012-10-30 The Regents Of The University Of California Methods and systems for genome-scale kinetic modeling
US7928189B2 (en) * 2008-05-05 2011-04-19 Ottawa Health Research Institute PCSK9 polypeptide fragment
US9182406B2 (en) * 2008-08-04 2015-11-10 Biodesy, Inc. Nonlinear optical detection of molecules comprising an unnatural amino acid possessing a hyperpolarizability
WO2010027641A2 (en) * 2008-08-15 2010-03-11 Georgetown University Na channels, disease, and related assays and compositions
US20120070443A1 (en) 2008-12-02 2012-03-22 University Of Utah Research Foundation Pde1 as a target therapeutic in heart disease
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
WO2010088393A2 (en) * 2009-01-28 2010-08-05 Antigen Express, Inc. Li-kay hybrid peptides that modulate the immune response to influenza
US8778329B2 (en) 2009-03-04 2014-07-15 The Trustees Of The University Of Pennsylvania Compositions comprising angiogenic factors and methods of use thereof
US20120149663A1 (en) 2009-08-18 2012-06-14 Georgetown University Boronic acid compositions and methods related to cancer
AU2010298036B2 (en) 2009-09-25 2015-05-21 Xoma Technology Ltd. Screening methods
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
JP2013507365A (ja) 2009-10-07 2013-03-04 サンフォード−バーナム メディカル リサーチ インスティテュート 血餅結合脂質化合物に関する方法および組成物
RU2539772C2 (ru) 2009-10-22 2015-01-27 Дженентек, Инк. Способы и композиции для модуляции гепсином стимулирующего макрофаги белка
TWI507524B (zh) 2009-11-30 2015-11-11 建南德克公司 診斷及治療腫瘤之組合物及方法
EP2512497A1 (en) 2009-12-18 2012-10-24 Sanford-Burnham Medical Research Institute Methods and compositions related to clot-binding compounds
ES2519348T3 (es) 2010-02-18 2014-11-06 Genentech, Inc. Antagonistas de neurregulina y uso de los mismos en el tratamiento del cáncer
AU2011221226A1 (en) 2010-02-23 2012-08-16 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2011115812A2 (en) * 2010-03-16 2011-09-22 Advanced Technologies And Regenerative Medicine, Llc Affinity peptides toward bmp-2
CN102958941A (zh) 2010-05-03 2013-03-06 霍夫曼-拉罗奇有限公司 用于肿瘤诊断和治疗的组合物和方法
US9376709B2 (en) 2010-07-26 2016-06-28 Biomatrica, Inc. Compositions for stabilizing DNA and RNA in blood and other biological samples during shipping and storage at ambient temperatures
EP2598661B1 (en) 2010-07-26 2017-09-27 Biomatrica, INC. Compositions for stabilizing dna, rna and proteins in saliva and other biological samples during shipping and storage at ambient temperatures
WO2012071436A1 (en) 2010-11-24 2012-05-31 Genentech, Inc. Method of treating autoimmune inflammatory disorders using il-23r loss-of-function mutants
US8112218B2 (en) * 2011-03-10 2012-02-07 Ford Global Technologies, Llc Method for controlling an engine
GB2503604B (en) 2011-03-21 2020-04-22 Biodesy Llc Classification of kinase inhibitors using second harmonic optical techniques
US20140323392A1 (en) 2011-03-28 2014-10-30 University Of Utah Research Foundation Methods and compositions related to inhibition of viral entry
US10352936B2 (en) 2011-04-14 2019-07-16 Apoplogic Pharmaceuticals, Inc. Use of tumor Fas expression to determine response to anti-cancer therapy
BR112014002353B1 (pt) 2011-08-01 2022-09-27 Genentech, Inc Usos de antagonistas de ligação do eixo pd-1 e inibidores de mek, composições farmacêuticas, e kit
CN103930781A (zh) 2011-09-15 2014-07-16 霍夫曼-拉罗奇有限公司 促进分化的方法
US9358250B2 (en) 2011-10-15 2016-06-07 Genentech, Inc. Methods of using SCD1 antagonists
CN104023760A (zh) 2011-10-28 2014-09-03 普莱萨格生命科学公司 药物递送方法
RU2014133547A (ru) 2012-01-18 2016-03-10 Дженентек, Инк. Способы применения модуляторов fgf19
BR112014019741A2 (pt) 2012-02-11 2020-12-22 Genentech, Inc Usos de um antagonista da via wnt, uso de uma terapia anticâncer, método de identificação de um indivíduo com câncer, métodos para prever, método de inibição da proliferação de uma célula de câncer, uso de um antagonista da translocação de r-spondina e antagonista da translocação de r-spondina isolado
HK1200093A1 (en) 2012-03-16 2015-07-31 霍夫曼-拉罗奇有限公司 Methods of treating melanoma with pak1 inhibitors
EP2825549B1 (en) 2012-03-16 2018-10-10 F. Hoffmann-La Roche SA Engineered conformationally-stabilized proteins
US9139863B2 (en) 2012-03-16 2015-09-22 Genentech, Inc. Engineered conformationally-stabilized proteins
GB2517857A (en) 2012-04-25 2015-03-04 Biodesy Inc Methods for detecting allosteric modulators of proteins
WO2013170191A1 (en) 2012-05-11 2013-11-14 Genentech, Inc. Methods of using antagonists of nad biosynthesis from nicotinamide
ES2742379T3 (es) 2012-05-31 2020-02-14 Hoffmann La Roche Procedimientos de tratamiento del cáncer usando antagonistas de unión al eje de PD-1 y antagonistas de VEGF
US9725703B2 (en) 2012-12-20 2017-08-08 Biomatrica, Inc. Formulations and methods for stabilizing PCR reagents
WO2014128235A1 (en) 2013-02-22 2014-08-28 F. Hoffmann-La Roche Ag Methods of treating cancer and preventing drug resistance
EP2968565A2 (en) 2013-03-14 2016-01-20 Genentech, Inc. Methods of treating cancer and preventing cancer drug resistance
PL2970422T3 (pl) 2013-03-15 2018-09-28 F.Hoffmann-La Roche Ag Polipeptydy IL-22 i białka fuzyjne IL-22 Fc i sposoby zastosowania
KR20150131269A (ko) 2013-03-15 2015-11-24 제넨테크, 인크. Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법
HK1214533A1 (zh) 2013-03-15 2016-07-29 基因泰克公司 治疗癌症和预防癌症耐药性的方法
TWI888366B (zh) 2013-07-16 2025-07-01 美商建南德克公司 利用pd-1軸結合拮抗劑及tigit抑制劑治療癌症之方法
US20150210772A1 (en) 2013-12-17 2015-07-30 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
WO2015116902A1 (en) 2014-01-31 2015-08-06 Genentech, Inc. G-protein coupled receptors in hedgehog signaling
US8961992B1 (en) 2014-04-02 2015-02-24 Tunitas Therapeutics, Inc. Epsigam fusion protein
MX2016014504A (es) 2014-05-05 2017-05-23 Regeneron Pharma Animales c5 y c3 humanizados.
KR20170005016A (ko) 2014-05-23 2017-01-11 제넨테크, 인크. MiT 바이오마커 및 그의 사용 방법
WO2015191632A1 (en) 2014-06-10 2015-12-17 Biomatrica, Inc. Stabilization of thrombocytes at ambient temperatures
WO2015191986A1 (en) 2014-06-13 2015-12-17 Genentech, Inc. Methods of treating and preventing cancer drug resistance
BR112017000672A2 (pt) 2014-07-15 2017-11-14 Genentech Inc composições para tratamento de câncer utilizando antagonistas de ligação de eixo pd-1 e inibidores de mek
US11219670B2 (en) 2014-09-05 2022-01-11 The Johns Hopkins University Targeting CAPN9/CAPNS2 activity as a therapeutic strategy for the treatment of myofibroblast differentiation and associated pathologies
SG11201704056XA (en) 2014-11-20 2017-06-29 Hoffmann La Roche Combination therapy of t cell activating bispecific antigen binding molecules cd3 abd folate receptor 1 (folr1) and pd-1 axis binding antagonists
EP3227337A1 (en) 2014-12-05 2017-10-11 F. Hoffmann-La Roche AG Methods and compositions for treating cancer using pd-1 axis antagonists and hpk1 antagonists
EP3237906B8 (en) 2014-12-23 2020-10-28 Bluelight Therapeutics, Inc. Attachment of proteins to interfaces for use in nonlinear optical detection
WO2016154629A1 (en) 2015-03-26 2016-09-29 Woman & Infants' Hospital Of Rhode Island Therapy for malignant disease
CN107921126A (zh) 2015-05-22 2018-04-17 转化药物开发有限责任公司 苯甲酰胺和活性化合物的组合物及其使用方法
WO2016205681A1 (en) 2015-06-19 2016-12-22 University Of Rochester Septin proteins as novel biomarkers for detection and treatment of müllerian cancers
JP2018529719A (ja) 2015-09-30 2018-10-11 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Ａｌｋ陰性がんを処置するためのｐｄ−１系結合アンタゴニストおよびａｌｋ阻害剤の組合せ
EP3371211B1 (en) 2015-11-04 2025-01-01 Icahn School of Medicine at Mount Sinai Rho-associated protein kinase ("rock") inhibitor for treating tumors and cancer, and identifying candidate subjects for such treatment
ES2946184T3 (es) 2015-12-08 2023-07-13 Biomatrica Inc Reducción de la velocidad de eritrosedimentación
CA3048202A1 (en) 2015-12-23 2017-06-29 Moonshot Pharma Llc Methods for inducing an immune response by inhibition of nonsense mediated decay
WO2017139329A1 (en) 2016-02-09 2017-08-17 Alexander Krantz Site-selective functionalization of proteins using traceless affinity lables
EP3448881B1 (en) 2016-04-26 2023-06-07 Icahn School of Medicine at Mount Sinai Treatment of hippo pathway mutant tumors and methods of identifying subjects as candidates for treatment
AU2017292646A1 (en) 2016-07-05 2019-02-07 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof
US10934261B2 (en) 2016-09-28 2021-03-02 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof
US10780080B2 (en) 2016-11-23 2020-09-22 Translational Drug Development, Llc Benzamide and active compound compositions and methods of use
CA3087881A1 (en) 2017-01-17 2018-07-26 Michael David FORREST Therapeutic inhibitors of the reverse mode of atp synthase
WO2018152496A1 (en) 2017-02-17 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Compositions and methods for the diagnosis and treatment of zika virus infection
WO2018157027A1 (en) 2017-02-27 2018-08-30 Regeneron Pharmaceuticals, Inc. Humanized model of kidney and liver disorders
CN106916205B (zh) * 2017-03-31 2020-10-13 重庆理工大学 抗菌六肽及其衍生物和应用
TW201841656A (zh) 2017-04-21 2018-12-01 美商建南德克公司 Ｋｌｋ５拮抗劑用於治療疾病之用途
EP4230649A3 (en) 2017-04-25 2023-10-25 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Antibodies and methods for the diagnosis and treatment of epstein barr virus infection
JP2020525434A (ja) 2017-06-22 2020-08-27 ムーンショット ファーマ エルエルシー アンレキサノクス及び免疫調節剤を含む組成物で癌を治療する方法
CA3099077A1 (en) 2017-07-13 2019-01-17 Michael David FORREST Therapeutic modulators of the reverse mode of atp synthase
US11827669B2 (en) 2017-07-19 2023-11-28 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies and methods for the diagnosis and treatment of hepatitis b virus infection
US12025615B2 (en) 2017-09-15 2024-07-02 Arizona Board Of Regents On Behalf Of Arizona State University Methods of classifying response to immunotherapy for cancer
US11400165B2 (en) 2017-11-04 2022-08-02 Advanced Proteome Therapeutics Inc. Composition and method for modifying polypeptides
US20190211098A1 (en) 2017-12-22 2019-07-11 Genentech, Inc. Use of pilra binding agents for treatment of a disease
CN110102263A (zh) * 2019-04-10 2019-08-09 中国药科大学 巯基乙胺功能化磁性氧化石墨烯吸附剂及其制备方法和应用
US20220241412A1 (en) 2019-05-24 2022-08-04 Pfizer Inc. Combination therapies using cdk inhibitors
EP4038222A4 (en) 2019-10-02 2023-10-18 Arizona Board of Regents on behalf of Arizona State University Methods and compositions for identifying neoantigens for use in treating and preventing cancer
JP2023501385A (ja) 2019-11-08 2023-01-18 ユニバーシティ オブ ピッツバーグ － オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 抗微生物ペプチドを含む組成物
AU2021363536A1 (en) 2020-10-20 2023-02-23 F. Hoffmann-La Roche Ag Combination therapy of PD-1 axis binding antagonists and LRRK2 inhitibors
US20220168293A1 (en) 2020-12-02 2022-06-02 Pfizer Inc. Time to resolution of axitinib-related adverse events
US12371463B2 (en) 2021-04-20 2025-07-29 University of Pittsburgh—of the Commonwealth System of Higher Education Methods and compositions for treatment of antibiotic-resistant bacterial infections
IL308015A (en) 2021-06-09 2023-12-01 Hoffmann La Roche Combination of a particular braf inhibitor (paradox breaker) and a pd-1 axis binding antagonist for use in the treatment of cancer
TW202327595A (zh) 2021-10-05 2023-07-16 美商輝瑞大藥廠 用於治療癌症之氮雜內醯胺化合物的組合
WO2026133192A1 (en) 2024-12-20 2026-06-25 Pfizer Inc. Combination therapies using cdk4 inhibitors with pd-1 axis binding antagonists

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3544404A (en) * 1968-01-05 1970-12-01 Burlington Industries Inc Method of making polypropylene bags
US4304692A (en) * 1978-07-24 1981-12-08 Armour Pharmaceutical Company Synthesis of biologically active peptides
US4226857A (en) * 1979-03-30 1980-10-07 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4282143A (en) * 1980-06-13 1981-08-04 American Home Products Corporation Octapeptides lowering growth hormone
CA1247080A (en) * 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
WO1984003506A1 (en) * 1983-03-08 1984-09-13 Commw Serum Lab Commission Antigenically active amino acid sequences
NZ207394A (en) * 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US4483964A (en) * 1983-06-20 1984-11-20 Chiron Corporation Reactor system and method for polynucleotide synthesis
US4507433A (en) * 1983-10-07 1985-03-26 The Johns Hopkins University Preparation of oligodeoxyribonucleoside alkyl or arylphosphonates
WO1986000991A1 (en) * 1984-07-24 1986-02-13 Commonwealth Serum Laboratories Commission Method for determining mimotopes
US4631211A (en) * 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
US5010175A (en) * 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
US4831211A (en) * 1988-06-08 1989-05-16 Rockwell International Corporation EMI/RFI sealed microphonics isolation apparatus and methods
US5182366A (en) * 1990-05-15 1993-01-26 Huebner Verena D Controlled synthesis of peptide mixtures using mixed resins
AU668347B2 (en) * 1990-11-21 1996-05-02 Torrey Pines Institute For Molecular Studies Synthesis of equimolar multiple oligomer mixtures, especially of oligopeptide mixtures

Also Published As

Publication number Publication date
JPH06507378A (ja) 1994-08-25
DE69130831D1 (de) 1999-03-11
WO1992009300A1 (en) 1992-06-11
EP0558671A1 (en) 1993-09-08
DK0558671T3 (da) 1999-09-13
DE69130831T2 (de) 1999-09-16
US5504190A (en) 1996-04-02
GR3030061T3 (en) 1999-07-30
CA2090860A1 (en) 1992-05-22
EP0558671B1 (en) 1999-01-27
ATE176239T1 (de) 1999-02-15
EP0558671A4 (en) 1994-05-11
AU9141891A (en) 1992-06-25
AU668347B2 (en) 1996-05-02
JP3523252B2 (ja) 2004-04-26
US5556762A (en) 1996-09-17
CA2090860C (en) 2003-09-16

Similar Documents

Publication Publication Date Title
AU668347B2 (en) Synthesis of equimolar multiple oligomer mixtures, especially of oligopeptide mixtures
CA2165561A1 (en) Peralkylated Oligopeptide Mixtures
CA2165694A1 (en) Erythropoietin analogs
DK0400583T3 (da) Imidazoquinoxalinoner,deres azaanaloger og fremgangsmåde til fremstilling deraf
DE59811531D1 (de) Verfahren zur Herstellung von Polyisocyanaten
DK0419111T3 (da) Kollagenmaterialer og fremgangsmåder til fremstilling heraf
DK0401844T3 (da) Resorberbare formlegemer og fremgangsmåde til fremstilling heraf
DK15589A (da) Kemiske forbindelser
DE69015504D1 (de) Stickstoffgasherstellungsverfahren.
DE69011531D1 (de) Von faktor vii abgeleitete peptide mit antihämostatischer wirkung.
DE69121666D1 (de) Verfahren zur Herstellung von Epoxy-Hepariden; die so hergestellten Produkte und diese enthaltende pharmazeutische Zusammensetzungen
DE3860999D1 (de) Zusammensetzungen von xylolgruppierungen enthaltenden polyarylalkanoligomeren und verfahren zu deren herstellung.
RU95108553A (ru) Способ получения нуклеозидных аналогов с использованием бициклических промежуточных продуктов
DE69010956D1 (de) Verfahren zur Synthese von Acylaminogruppen enthaltenden Siliziumverbindungen.
DK63689D0 (da) Fremgangsmaade til modificering af en molekylesigte
ATE92082T1 (de) Verfahren zur koernung von azobisamidinsalzen.
IT8820542A0 (it) Processo diastereoselettivo per lapreparazione di intermedi utili per la sintesi di derivati peptidici.
FI881111A0 (fi) Foerfarande foer framstaellning av polyklorfosfazen.
DE68900471D1 (de) Stickstoffgasherstellungsverfahren.
NO962542L (no) Forbedret fremgangsmåte for syntese av 2-amino-3,5-dihydro-7-substituerte 4H-pyrrolo (3,2-d) pyrimidin-4-oner
DK0635491T3 (da) (Thia)cycloalkylab indoler, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende disse forbindelser.
FI893758A7 (fi) Menetelmä pentaerytryylitetrakis-/3-(3,5-di-t-butyyli-4-hydroksifenyyl i) propionaatin/ottamiseksi talteen mainitun tuotteen synteesissä saad usta reaktiomassasta
DK0379288T3 (da) Fremgangsmåde og mellemprodukter for isopropyl 3S-amino-2R-hydroxyalkanoater
DK580586D0 (da) Partikelformet detergentenzymprodukt og fremgangsmaade til fremstilling deraf
DK235586D0 (da) Partikelformet detergentenzymprodukt og fremgangsmaade til fremstilling deraf

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 558671

Country of ref document: ES